Back to Search
Start Over
Enhancing innate immunity against virus in times of COVID-19: trying to untangle facts from fictions
- Source :
- The World Allergy Organization Journal, World Allergy Organization Journal, Vol 13, Iss 11, Pp 100476-(2020), World Allergy Organization Journal
- Publication Year :
- 2020
- Publisher :
- Published by Elsevier Inc. on behalf of World Allergy Organization., 2020.
-
Abstract
- Introduction In light of the current COVID-19 pandemic, during which the world is confronted with a new, highly contagious virus that suppresses innate immunity as one of its initial virulence mechanisms, thus escaping from first-line human defense mechanisms, enhancing innate immunity seems a good preventive strategy. Methods Without the intention to write an official systematic review, but more to give an overview of possible strategies, in this review article we discuss several interventions that might stimulate innate immunity and thus our defense against (viral) respiratory tract infections. Some of these interventions can also stimulate the adaptive T- and B-cell responses, but our main focus is on the innate part of immunity. We divide the reviewed interventions into: 1) lifestyle related (exercise, >7 h sleep, forest walking, meditation/mindfulness, vitamin supplementation); 2) Non-specific immune stimulants (letting fever advance, bacterial vaccines, probiotics, dialyzable leukocyte extract, pidotimod), and 3) specific vaccines with heterologous effect (BCG vaccine, mumps-measles-rubeola vaccine, etc). Results For each of these interventions we briefly comment on their definition, possible mechanisms and evidence of clinical efficacy or lack of it, especially focusing on respiratory tract infections, viral infections, and eventually a reduced mortality in severe respiratory infections in the intensive care unit. At the end, a summary table demonstrates the best trials supporting (or not) clinical evidence. Conclusion Several interventions have some degree of evidence for enhancing the innate immune response and thus conveying possible benefit, but specific trials in COVID-19 should be conducted to support solid recommendations.
- Subjects :
- BV, Bacterial vaccine
mindfulness
ACE2, Angiotensin converting enzime-2
Systemic inflammatory response syndrome, TCR :T-cell receptor
APC, Antigen-presenting cell
Heat shock proteins, HLA-DR
bacterial vaccine
Immunoglobulin, IGFBP6
immune response
DLE, Dialyzable leukocyte extract
PPD, Purified protein derivative (tuberculin)
trained immunity
MCP-1, Monocyte chemoattractant protein-1
NK, Natural killer
Gαs: G protein coupled receptor alfa-subunits, HSP
Rapid eye movement, RIPK2
Pandemic
Immunology and Allergy
TNF-α, Tumor necrosis factor alpha
R0 : Basic reproduction number, REM
PUFA, Polyunsaturated fatty acid
NOD2, Nucleotide-binding oligomerization domain-containing protein 2
Toll-like receptor
Reactive oxygen species, SARS-CoV-2
Respiratory tract infections
exercise
CNS, Central nervous system
Interferon, IG
MMR
DC, Dendritic cell
Bacterial vaccine
Reactive nitrogen species, ROS
PKC, Protein kinase C
BCG, Bacillus Calmette-Guérin
DAMPs, Damage-associated molecular patterns
TLR, Toll-like receptor
Pulmonary and Respiratory Medicine
lcsh:Immunologic diseases. Allergy
medicine.medical_specialty
Interleukin, MBSR
CCL-5, Chemokine (C-C motif) ligand 5
Immunology
Insulin-like growth-factor-binding-protein 6, IL
Major histocompatibility complex class II cell surface receptor, ICAM-1
COVID-19, Coronavirus disease-2019
Article
OxPhos: Oxidative phosphorylation, PAMPs
Immune system
Immunity
NK-cell
URTI, Upper-respiratory tract infection
Bacillus Calmette-Guérin
medicine
innate
Intercellular adhesion molecule type 1, IFN
MODS, Multi-organ dysfunction syndrome
NF-κB, Nuclear factor kappaB
sleep
Intensive care medicine
Innate immune system
Severe acute respiratory syndrome coronavirus 2, SIRS
business.industry
CI, Confidence interval
Pathogen-associated molecular patterns, PBMC
COVID-19
Mindfulness-based stress reduction, mCa++: Intramitochondrial calcium
Review article
MyD88, Myeloid differentiation primary response 88
TRPV, Thermolabile calcium channels
CXCR3A, CXC chemokine receptor 3A
Receptor iteracting serine/threonine kinase 2, RNA
Ribonucleic acid, RNS
business
lcsh:RC581-607
Peripheral blood mononuclear cell, PI3K/Akt: Phosphatidylinositol 3-kinase pathway
OR, Odds ratio
Th, T helper-cell
Subjects
Details
- Language :
- English
- ISSN :
- 19394551
- Database :
- OpenAIRE
- Journal :
- The World Allergy Organization Journal
- Accession number :
- edsair.doi.dedup.....45da142c5e67428ba047c0a296c7c2b7